Company: APXIF
Filing Date: 2025-07-03
Form Type: F-4/A
Source: 0001213900-25-061545
Chunk: 218

Company: APx Acquisition Corp. I
Filing Date: 2025-07-03
Form: F-4/A
Chunk 218
---
 by the Sponsor (which shares were purchased in connection with the Sponsor Alliance), which have an approximate aggregate market value of $ as of the Record Date, and the 970,312 SPAC Class A Ordinary Shares held by the Initial Sponsor (which were purchased in connection with the IPO and which were retained in connection with the Sponsor Alliance), which have an approximate aggregate market value of $ as of the Record Date, will expire worthless. As a result, the Initial Shareholders have an aggregate of up to $ at risk as of the Record Date that depends on the completion of an initial business combination on or prior to the Extended Date. In contrast, Public Shareholders would receive approximately $ per share if the Trust Account is liquidated, calculated as of the Record Date; •the Sponsor has made Working Capital Loans to APx that may be repaid upon completion of the Business Combination, without interest, or at the lender’s discretion, converted upon completion of the Business Combination into up to 1,500,000 warrants of the post -businesscombination entity at a price of $1.00 per warrant at the option of the lender. The warrants would be identical to the Private Placement Warrants. On September8, 2023, APx issued the Working Capital Promissory Note. On February9, 2024, APx issued the Amended and Restated Note, amending and restating the Working Capital Promissory Note 88 to increase the maximum principal amount from $500,000 to $2,000,000 and to provide that, in addition to funding working capital needs, amounts under the Amended and Restated Note may be used for the purposes of making one or more payments to Continental Stock Transfer & Trust Company, a New York limited liability trust company, as Extension Payments (as defined in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on November29, 2023, as amended). As of March31, 2025, $1,743,499 has been drawn under the Amended and Restated Promissory Note. If APx does not complete an initial business combination, it is unlikely that Sponsor will recover funds drawn by APx under the Amended and Restated Note; •on August17, 2023, Mr. Bransfield, as borrower, entered into the Sponsor Loan Agreement. Mr. Bransfield, as borrower, also entered into a pledge and security agreement, with Bioceres Group PLC, as the lender, and UG Holdings LLC,